No black box warning on record for Griseofulvin

As of the latest FDA labeling reviewed, Griseofulvin (GRISEOFULVIN (MICROSIZE)) does not carry a black box warning. Standard warnings and precautions still apply — see the full Griseofulvin medicine page for the complete safety profile.

Other warnings & precautions

Warnings Prophylactic Usage: Safety and efficacy of prophylactic use of this drug has not been established. Chronic feeding of griseofulvin, at levels ranging from 0.5-2.5% of the diet, resulted in the development of liver tumors in several strains of mice, particularly in males. Smaller particle sizes result in an enhanced effect. Lower oral dosage levels have not been tested. Subcutaneous admini

No black box warning on record for Griseofulvin

Other warnings & precautions

Warnings Prophylactic Usage: Safety and efficacy of prophylactic use of this drug has not been established. Chronic feeding of griseofulvin, at levels ranging from 0.5-2.5% of the diet, resulted in the development of liver tumors in several strains of mice, particularly in males. Smaller particle sizes result in an enhanced effect. Lower oral dosage levels have not been tested. Subcutaneous admini

Griseofulvin Black Box Warning

No black box warning on record for Griseofulvin

Other warnings & precautions

Griseofulvin Black Box Warning

No black box warning on record for Griseofulvin

Other warnings & precautions